MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
12 mai 2022 07h00 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa First Phase 2 trial in hidradenitis suppurativa using the...